HALO PEER ANALYSIS

Halozyme Therapeutics Inc — metric-by-metric comparison with peers and the industry median

HALOHalozyme Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

HALOIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	HALO	CSL	TLX	MSB	Ind. Median
P/E	28.31●	30.04	—	—	18.00
P/B	44.96	2.25●	6.26	—	3.60
EV/EBITDA	18.76	10.37●	118.24	—	15.20
P/S	6.55	2.67●	3.18	30.99	10.43

Financial Health
Metric	HALO	CSL	TLX	MSB	Ind. Median
Current Ratio	2.76●	2.57	1.43	—	5.90
Debt/Equity	976.5%	67.4%●	112.3%	—	10.9%
NetDebt/EBITDA	2.93	2.22●	13.13	—	1.15

Profitability
Metric	HALO	CSL	TLX	MSB	Ind. Median
Net Margin	23.1%●	9.2%	-0.9%	-115.3%	-125.7%
ROE	99.4%●	7.7%	-1.8%	-11.3%	-47.5%
ROA	14.3%●	3.8%	-0.7%	-8.6%	-35.8%
EBITDA Margin	41.4%●	32.8%	3.0%	-76.6%	-105.8%

Growth + Dividend
Metric	HALO	CSL	TLX	MSB	Ind. Median
Rev. Growth	39.1%	4.8%	56.3%	410.4%●	5.1%
NI Growth	-28.1%●	-39.4%	—	—	12.1%
Div. Yield	—	2.5%●	—	0.0%	0.2%
Payout	—	103.1%	—	0.0%	0.0%

Valuation
Metric	HALO	NUVL	IBRX	CORT	PTGX	APGE	Ind. Median
P/E	28.31●	—	—	202.62	—	—	18.00
P/B	44.96	8.29	-10.39●	15.21	15.06	7.39	3.60
EV/EBITDA	18.76●	—	—	662.45	—	—	15.20
P/S	6.55●	—	64.10	12.62	133.32	—	10.43

Financial Health
Metric	HALO	NUVL	IBRX	CORT	PTGX	APGE	Ind. Median
Current Ratio	2.76	16.14	6.67	2.86	17.76	32.59●	5.90
Debt/Equity	976.5%	—	-129.3%●	1.5%	1.5%	0.6%	10.9%
NetDebt/EBITDA	2.93	—	-1.02	-23.21●	4.72	3.86	1.15

Profitability
Metric	HALO	NUVL	IBRX	CORT	PTGX	APGE	Ind. Median
Net Margin	23.1%●	—	-606.2%	6.2%	-154.9%	—	-125.7%
ROE	99.4%●	-41.2%	—	7.3%	-17.1%	-28.5%	-47.5%
ROA	14.3%●	-36.9%	-179.8%	5.8%	-15.9%	-27.4%	-35.8%
EBITDA Margin	41.4%●	—	-515.2%	1.8%	-153.8%	—	-105.8%

Growth + Dividend
Metric	HALO	NUVL	IBRX	CORT	PTGX	APGE	Ind. Median
Rev. Growth	39.1%	—	351.5%●	12.2%	-64.4%	-100.0%	5.1%
NI Growth	-28.1%●	—	—	-64.0%	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on HALO

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.